Research programme: lipid-emulsion therapeutics - ResQ Pharma

Drug Profile

Research programme: lipid-emulsion therapeutics - ResQ Pharma

Alternative Names: LipidRescue Therapy

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ResQ Pharma
  • Class Lipids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Poisoning
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Poisoning

Most Recent Events

  • 15 Jun 2017 Research programme: lipid-emulsion therapeutics - ResQ Pharma receives Orphan Drug status for Poisoning in USA
  • 24 May 2016 ResQ Pharma has patent protection for LipidRescue™ therapy in USA
  • 20 May 2016 Preclinical trials in Poisoning in Ireland (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top